Global Calprotectin Testing Market Soars to New Heights: Projected to Reach USD 360.2 Billion by 2033 with a Steady CAGR of 6% | FMI

The global calprotectin testing market, valued at USD 201.1 billion in 2023, is on a trajectory to nearly double, projected to reach an impressive USD 360.2 billion by 2033. With a compound annual growth rate (CAGR) of 6% over the forecast period, this surge underscores the essential role of calprotectin testing in modern healthcare, driven by an increased demand for early detection of gastrointestinal disorders.

Calprotectin testing has emerged as a fundamental diagnostic tool, particularly for its efficacy in identifying gastrointestinal conditions early on. As the prevalence of gastrointestinal disorders rises, so does the need for accurate, preventive healthcare solutions. Calprotectin testing meets this need, allowing healthcare providers to identify issues proactively, benefiting both patient outcomes and the efficiency of healthcare systems worldwide.

The current growth trend in the calprotectin testing market aligns with a larger transformation in diagnostic healthcare: the shift towards early detection and preventive care. The value placed on timely diagnoses is motivating patients and providers alike to adopt calprotectin testing, paving the way for advancements in gastrointestinal diagnostics and treatment planning.

With its reliable accuracy and relevance, calprotectin testing is set to play a pivotal role in the future of healthcare diagnostics. As awareness and adoption continue to expand, the market is positioned for sustained growth in the coming decade, further establishing calprotectin testing as a cornerstone of early diagnostic practices across the healthcare sector.

Recent Trends in the Global Calprotectin Testing Market:

The several notable trends in the global market are as follows:

• There is rising demand for non-invasive diagnostic devices by healthcare providers and patients to produce quick and accurate results.
• The prevalence of inflammatory bowel disease is growing rapidly. Therefore, the demand for calprotectin testing is increasing to monitor patients’ chronic health.
• The innovation of advanced technology devices is more reliable and tract patients’ health accurately.
• Adopting automation in calprotectin testing reduces error risk, detects efficiently, and increases productivity.

Surge in Market Needs: Discover Comprehensive Analysis and Insights in Our Detailed Report!

Key Takeaways:

• The calprotectin testing market is securing a valuation of USD 360.2 billion with a CAGR of 6% by 2033.
• The United States is anticipated to lead the global market by registering a share of 25.7% by 2033.
• Japan is anticipated to register a share of 3.1% in the global market during the forecast period.
• In the historic period, the market captured a CAGR of 5.3% between 2018 and 2022.

Key Players are Executing Plans to Rise the Market Size:

The key players are executing various plans to upsurge the global market are:

• New Product Launches: key players are developing user-friendly, sustainable, and accurate testing devices in the market. They are launching these testing tools to satisfy patients’ requirements.
• Collaboration: Key companies collaborate with stakeholders, research organizations, and hospitals to enhance product quality. These collaborations help them to reach relevant customers and increase sales.
• Promotions and Marketing: Key players invest in promotional and marketing to expand their business and brand value. They promote their products on social media and educate patients about the benefits of their products.

These are a few strategies key players adopt to increase the market size:

• Actim Oy
• Calpro AS
• BÜHLMANN Laboratories AG
• EagleBio
• CerTest Biotec S.L.
• EUROIMMUN Medizinische Labordiagnostika AG
• Boditech Med Inc.
• Biohit Oyj
• American Laboratory Products Company, Ltd.
• DIAsource ImmunoAssays S.A
• R-Biopharm AG.

Recent Developments in the Global Market are:

• In 2020, Biohit Oyj launched its new product Calprotectin ELISA kit. It is designed to collect human samples to monitor inflammatory bowel disease.
• In 2021, Techlab Inc launched Enteric BioFire FilmArray Panel to detect gastrointestinal infections.
• In 2021, EKF Diagnostics launched its point-of-care device to measure calprotectin. This device provides accurate and fast results to monitor patients’ diseases.

Calprotectin Testing Market by Category:

By Test Kits:

• Calprotectin ELISA Test Kits
• Calprotectin Rapid Testing Kits

By Sample:

• Stool, Blood Serum/Plasma
• Other Biological Samples

By Indication:

• Irritable Bowel Syndrome
• Ulcerative Colitis
• Crohn’s Disease
• Colorectal Cancer

By End User:

• Hospitals
• Diagnostic Laboratories
• Specialty Clinics

Region:

• North America
• Europe
• Latin America
• Asia Pacific
• The Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube